Iran J Otorhinolaryngol
Department of Otolaryngology, Head and Neck Surgery, Shahid Beheshti University of Medical Sciences, Taleghani Hospital, Tehran, Iran.
Published: September 2023
Introduction: Considering the inconsistent results regarding the association between the severity and duration of olfactory dysfunction (OD), and the viral load in coronavirus disease 2019 (COVID-19) patients, we aimed to conduct this study.
Materials And Methods: This is a prospective cohort study in which COVID-19 patients were evaluated for the initial cycle threshold value (Ct values) measured by the nasopharyngeal samples along with olfactory function measured by the University of Pennsylvania Smell Identification Test (UPSIT) within 2 months of COVID-19 onset.
Results: Among 309 COVID-19 patients who were included in this study, 108 (34.9%), 112 (36.2%) and 89 (28.8%) were normosmic, hyposmic, and anosmic, respectively based on the UPSIT. The severity of COVID-19 and the rate of hospitalization were higher in anosmic patients (p<0.0001, and p<0.0001, respectively). Moreover, significant associations between the initial Ct value and the severity of OD at admission and follow-ups were detected (p<0.0001 and p<0.0001, respectively). Anosmic patients had higher Ct values in comparison with hyposmic (approx. 3-fold) and normosmic (approx. 12-fold) patients. The recovery rate after one- and two-month follow-ups was 47% and 84%, respectively. At the follow-ups, OD-recovered patients significantly had lower Ct values (mean Ct value: 27.79 ± 2 and 28.21 ± 2.08) in comparison with those who have not recovered yet (mean Ct value: 30.19 ± 3.36, and 33.6 ± 3.37) (p<0.0001, and p<0.0001, respectively).
Conclusions: Ct value seems to be a significant factor not only in predicting OD severity in COVID-19 patients but also in the OD recovery duration. This finding may be helpful to investigate the underlying mechanisms of OD in COVID-19 patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712552 | PMC |
http://dx.doi.org/10.22038/IJORL.2023.71462.3429 | DOI Listing |
J Hand Ther
March 2025
Schulich School of Medicine and Dentistry, Western University, London, Canada; Department of Surgery, London Health Sciences Centre, London, Canada. Electronic address:
Background: The COVID-19 pandemic prompted a shift in healthcare delivery, necessitating the rapid adoption of technology, including telerehabilitation. This study focused on understanding the current perspectives and experiences of hand therapists in Canada and the United States regarding implementation of telerehabilitation in hand therapy, traditionally reliant on in-person interactions.
Purpose: The study aimed to assess the utilization, perceptions, and barriers of telerehabilitation among hand therapists, providing insights into challenges and opportunities for incorporation into practices.
J Stroke Cerebrovasc Dis
March 2025
Department of Neurology, Division of Neurocritical Care, University of North Carolina, Chapel Hill, NC, USA. Electronic address:
Resuscitation
March 2025
Parkland Health System, Dallas, TX; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Background: Survival after out-of-hospital cardiac arrest (OHCA) decreased sharply in 2020 during the COVID-19 pandemic. It is unknown if survival recovered to pre-pandemic levels, or how recovery varied by community racial and ethnic composition.
Methods: We analyzed adults with non-traumatic OHCA from 2015-2022 in the Cardiac Arrest Registry to Enhance Survival using multivariable regression models with generalized estimation equations to calculate risk-adjusted rates of survival to discharge during 2015-2019 (pre-pandemic period) versus 2020, 2021, and 2022.
Gene
March 2025
Health Sciences University, Ankara Bilkent City Hospital, Department of Anesthesiology and Reanimation, Ankara, Turkey.
Background: Coronavirus disease-2019 (COVID-19) causes severe hypoxemia. Unlike normal pneumonia, pneumonia due to COVID-19 causes oxygen deprivation without breathing difficulties (i.e.
View Article and Find Full Text PDFVaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare, but serious, complication of the ChAdOx1 nCOV-19 vaccine. In Australia, the diagnosis of VITT required the detection of antibodies against platelet factor 4 (PF4) in plasma using a PF4/polyanion ELISA. Half of the patients, fulfilling clinical criteria of VITT, tested positive in this ELISA and another third tested positive in platelet activation assays, highlighting limitations in the assays used for VITT.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.